AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) associated with progression of diabetic retinopathy
Number of subjects: 1211
Study 19509350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study 16512939 — intervention group
Group type: EXPERIMENTAL
Intervention: Algal oil containing 1.5 g DHA and 0.6 g DPA, 4 g oil/d for 4 weeks
Number of subjects: 79
Study 16512939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15165387 — intervention group
Group type: EXPERIMENTAL
Intervention: RICE method plus an 820‐nm GaA1As diode laser with a radiant power output of 40 mW at 16 Hz
Number of subjects: 47
Study 15165387 — intervention group
Group type: COMPARATOR
Intervention: RICE method plus placebo laser
Number of subjects: 47
Study 15165387 — intervention group
Group type: COMPARATOR
Intervention: Conventional initial treatment (RICE, rest, ice, compression, elevation)
Number of subjects: 47
Study 11167172 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (100 microg kg(‐1) min(‐1))
Number of subjects: 0
Study 11167172 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (1.0%, end‐tidal) with nitrous oxide 66%
Number of subjects: 0
Study 9263157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 30 mg ketoprofen plaster once daily for 5 days (n = 30)
Number of subjects: 60
Study 9263157 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 50 mg ketoprofen (n = 30)
Number of subjects: 60
Study 8390329 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% with adrenaline 1:200,000 plus 0.1 mEq.ml‐1 sodium bicarbonate
Number of subjects: 116
Study 8390329 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2% with adrenaline 1:200,000 without sodium bicarbonate
Number of subjects: 116
Study 3655305 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day)
Number of subjects: 64
Study 3655305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29498480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclometh 0.2%
Number of subjects: 21
Study 29498480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29498480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclometh 0.1%
Number of subjects: 21
Study 29498480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclometh 0.2% and Diclometh 0.1%
Number of subjects: 21
Study 28817132 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma of argon treatment
Number of subjects: 20
Study 28817132 — intervention group
Group type: COMPARATOR
Intervention: Cleaning protocol by steam (Control)
Number of subjects: 20
Study 25737017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 72
Study 25737017 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 24040851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalfurafine 5 μg intravenously after each hemodialysis session
Number of subjects: 146
Study 24040851 — intervention group
Group type: COMPARATOR
Intervention: Control group (81 ESRD patients without uremic pruritus)
Number of subjects: 146
Study 24040851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalfurafine and Control group
Number of subjects: 146
Study 21385240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review by community pharmacists
Number of subjects: 498
Study 21385240 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 498
Study 19194354 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0
Study 19194354 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 0
Study 16136309 — intervention group
Group type: EXPERIMENTAL
Intervention: monoHER (100 mg/m2 to 1,500 mg/m2, administered as an i.v. infusion in 10 min)
Number of subjects: 9
Study 16136309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml dextrose 5%)
Number of subjects: 9
Study 12933531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 53
Study 12933531 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) with micronized progesterone (MP, 100 mg) and conjugated equine estrogen (CEE, 0.625 mg)
Number of subjects: 53
Study 11086281 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg tablets) taken daily for three months, during or outside meals
Number of subjects: 3223
Study 11086281 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg tablets)
Number of subjects: 3223
Study 9542771 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 grams of creatine monohydrate daily for three days)
Number of subjects: 12
Study 9542771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9542771 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12
Study 8268595 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (2 mg/kg/hr)
Number of subjects: 25
Study 8268595 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium heparin 3 mg/kg)
Number of subjects: 25
Study 3855337 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 0
Study 3855337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 0
Study 30223046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity circuit resistance training (HVCRT)
Number of subjects: 30
Study 30223046 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state, moderate-intensity treadmill training (TM)
Number of subjects: 30
Study 30223046 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 30
Study 27020109 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment plans
Number of subjects: 35
Study 27020109 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plans
Number of subjects: 35
Study 27020109 — intervention group
Group type: COMPARATOR
Intervention: Standard and experimental arms
Number of subjects: 35
Study 24935755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with smoking abstinence-contingent incentives (expired CO < 6 ppm; urinary cotinine < 30 ng/ml) for 4 weeks
Number of subjects: 45
Study 24935755 — intervention group
Group type: COMPARATOR
Intervention: Monitoring with behavioral support
Number of subjects: 45
Study 24935755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 45
Study 23227687 — intervention group
Group type: COMPARATOR
Intervention: Single-needle group (1 silver needle, 18 cm length, 1.1 mm diameter)
Number of subjects: 36
Study 23227687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-needle group (1 silver needle + 4 additional needles, 2 cm apart)
Number of subjects: 36
Study 23227687 — intervention group
Group type: COMPARATOR
Intervention: Single-needle group (1 silver needle)
Number of subjects: 36
Study 23227687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-needle group (1 silver needle + 4 additional needles)
Number of subjects: 36
Study 20706150 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study 18931203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 213
Study 18931203 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 213
Study 15975487 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing formula (n=25)
Number of subjects: 50
Study 15975487 — intervention group
Group type: COMPARATOR
Intervention: Conventional early enteral nutrition (n=25)
Number of subjects: 50
Study 12451199 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-1189 100 mg/day
Number of subjects: 64
Study 12451199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12451199 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-1189 50 mg/day
Number of subjects: 64
Study 12451199 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-1189
Number of subjects: 64
Study 10359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus group drug counseling (GDC)
Number of subjects: 487
Study 10359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus GDC
Number of subjects: 487
Study 10359461 — intervention group
Group type: COMPARATOR
Intervention: GDC alone
Number of subjects: 487
Study 10359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus GDC
Number of subjects: 487
Study 10359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive‐expressive therapy plus GDC
Number of subjects: 487
Study 7573718 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (AR)
Number of subjects: 13
Study 7573718 — intervention group
Group type: COMPARATOR
Intervention: Quinine (QN)
Number of subjects: 13
Study 1664346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 4 mg daily)
Number of subjects: 35
Study 1664346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7066139 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 126
Study 7066139 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Number of subjects: 126
Study 7066139 — intervention group
Group type: EXPERIMENTAL
Intervention: self-administered i.v. pethidine
Number of subjects: 126
Study 30407996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac (IVK)
Number of subjects: 100
Study 30407996 — intervention group
Group type: COMPARATOR
Intervention: Control (no IVK)
Number of subjects: 100
Study 30407996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 27787671 — intervention group
Group type: EXPERIMENTAL
Intervention: Child intervention condition
Number of subjects: 267
Study 27787671 — intervention group
Group type: EXPERIMENTAL
Intervention: Child + parent intervention condition
Number of subjects: 267
Study 27787671 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 267
Study 26313301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 400
Study 26313301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 24760263 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape- and pressure-based orthoses (experimental)
Number of subjects: 130
Study 24760263 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care A5513 orthoses (control)
Number of subjects: 130
Study 23159967 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine treatment and H. pylori eradication treatment
Number of subjects: 64
Study 23159967 — intervention group
Group type: COMPARATOR
Intervention: Migraine treatment and placebo (control)
Number of subjects: 64
Study 20069517 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized back school programme
Number of subjects: 360
Study 17303309 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training/retraining
Number of subjects: 2729
Study 17303309 — intervention group
Group type: EXPERIMENTAL
Intervention: AED training/retraining
Number of subjects: 2729
Study 17303309 — intervention group
Group type: COMPARATOR
Intervention: Further retraining intervals (3, 6, 9, and 12 months)
Number of subjects: 2729
Study 15902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive pc‐based training program
Number of subjects: 125
Study 15902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in outpatient clinics
Number of subjects: 125
Study 15902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group training during inpatient stay
Number of subjects: 125
Study 15902596 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI phantoms
Number of subjects: 125
Study 15902596 — intervention group
Group type: COMPARATOR
Intervention: Suppliers medication leaflet
Number of subjects: 125
Study 12436350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 372
Study 12436350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 10628247 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of procaine spirit
Number of subjects: 100
Study 10628247 — intervention group
Group type: COMPARATOR
Intervention: Cleansing with water (Control)
Number of subjects: 100
Study 7720296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (100 mcg)
Number of subjects: 41
Study 7720296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2119419 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin once daily
Number of subjects: 40
Study 2119419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + resins
Number of subjects: 40
Study 2119419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2119419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pravastatin and resins
Number of subjects: 40
Study 7435893 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg in a single dose prior to bypass
Number of subjects: 0
Study 7435893 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving saline
Number of subjects: 0
Study 29073688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature of 34°C
Number of subjects: 0
Study 29073688 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature of 28°C
Number of subjects: 0
Study 26657442 — intervention group
Group type: COMPARATOR
Intervention: NHS-funded patient
Number of subjects: 119
Study 26657442 — intervention group
Group type: COMPARATOR
Intervention: Privately-funded patient
Number of subjects: 119
Study 26657442 — intervention group
Group type: COMPARATOR
Intervention: Undisclosed-fee patient
Number of subjects: 119
Study 23473342 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam (1 mg/kg PO)
Number of subjects: 40
Study 23473342 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin (15 mg/kg PO)
Number of subjects: 40
Study 23473342 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam (1 mg/kg) and gabapentin (15 mg/kg) PO
Number of subjects: 40
Study 23473342 — intervention group
Group type: EXPERIMENTAL
Intervention: flunixin (2.2 mg/kg IV)
Number of subjects: 40
Study 23473342 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 22331114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 0.15% ophthalmic gel
Number of subjects: 33
Study 22331114 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears without preservative
Number of subjects: 33
Study 19487950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g i.v. paracetamol 20 min before and 4, 10 and 16 h after the end of the operation.
Number of subjects: 87
Study 19487950 — intervention group
Group type: COMPARATOR
Intervention: 1 g i.v. metamizol scheduled at the same time points as paracetamol.
Number of subjects: 87
Study 19487950 — intervention group
Group type: COMPARATOR
Intervention: Placebo scheduled at the same time points as paracetamol.
Number of subjects: 87
Study 19487950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g i.v. paracetamol
Number of subjects: 87
Study 19487950 — intervention group
Group type: COMPARATOR
Intervention: 1 g i.v. metamizol
Number of subjects: 87
Study 19487950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg BID for 2 weeks escalating to 40 mg BID for 6 weeks
Number of subjects: 516
Study 17160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg BID for 8 weeks
Number of subjects: 516
Study 17160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg QD for 2 weeks escalating to 40 mg BID for 6 weeks
Number of subjects: 516
Study 17160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (any regimen)
Number of subjects: 516
Study 17160693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 12892566 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation plus best care in general practice
Number of subjects: 1350
Study 12892566 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes (Back to Fitness) plus best care in general practice
Number of subjects: 1350
Study 12892566 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation followed by exercise plus best care in general practice
Number of subjects: 1350
Study 12892566 — intervention group
Group type: COMPARATOR
Intervention: Best care in general practice only
Number of subjects: 1350
Study 11145489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (two 180 microg/kg boluses 10 min apart and a continuous infusion of 2.0 microg/kg/min for 18‐24 h)
Number of subjects: 2064
Study 11145489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 11145489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study 9529558 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied antioxidants (combinations of alpha‐glycosylrutin, ferulic acid, and tocopheryl acetate)
Number of subjects: 30
Study 9529558 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only (control group)
Number of subjects: 30
Study 14628737 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interferon-beta (HuIFN-beta)
Number of subjects: 30
Study 2988393 — intervention group
Group type: COMPARATOR
Intervention: Improved diet in calcium and Vitamin D (Group I)
Number of subjects: 28
Study 2988393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular supplement of 30 mg of Vitamin D3 in monthly injections of 5 or 10 mg (Group II)
Number of subjects: 28
Study 29754530 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 mmHg medical compression stockings (group A)
Number of subjects: 94
Study 29754530 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mmHg medical compression stockings (group B)
Number of subjects: 94
Study 29462997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroin protein enzymatic hydrolysate (FPEH) at doses of 280 mg, 400 mg, and 600 mg per day for 3 weeks
Number of subjects: 0
Study 29462997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg FPEH)
Number of subjects: 0
Study 26725694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up interventions and nursing education
Number of subjects: 71
Study 26725694 — intervention group
Group type: COMPARATOR
Intervention: Routine interventions (Control)
Number of subjects: 71
Study 25826729 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intervention consisting of a very-low-energy diet for the initial 6 weeks followed by a hypocaloric diet, combined with a weekly group multidisciplinary programme (n=27)
Number of subjects: 49
Study 25826729 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving recommendations for weight loss and the same printed material (n=22)
Number of subjects: 49
Study 22991952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Alert (PAAL) intervention
Number of subjects: 300
Study 19825849 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg IM methylprednisolone acetate
Number of subjects: 222
Study 19825849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 18953215 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA plus targeted disease management (DM group)
Number of subjects: 133
Study 18953215 — intervention group
Group type: COMPARATOR
Intervention: HRA plus information about worksite health promotion programs (HRA group)
Number of subjects: 133
Study 16428154 — intervention group
Group type: COMPARATOR
Intervention: Oral terbinafine 250 mg/day for 16 weeks
Number of subjects: 80
Study 16428154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral terbinafine 250 mg/day for 16 weeks and topical ciclopirox nail lacquer once daily for 9 months
Number of subjects: 80
Study 12598341 — intervention group
Group type: EXPERIMENTAL
Intervention: LV + 5‐FU + RT (Group A)
Number of subjects: 207
Study 12598341 — intervention group
Group type: COMPARATOR
Intervention: LV + 5‐FU + RT + IFN‐alpha (Group B)
Number of subjects: 207
Study 10378089 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (2,3 dimercaptosuccinic acid)
Number of subjects: 39
Study 10378089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8892765 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (3 sessions per week for 12 weeks)
Number of subjects: 36
Study 8892765 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program + calcium heparin 12,500 IU subcutaneously 20 to 30 minutes before each exercise session
Number of subjects: 36
Study 8892765 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 36
Study 1845132 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (15-1000 micrograms/m2)
Number of subjects: 65
Study 1845132 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3 (60 micrograms/m2, s.c.)
Number of subjects: 65
Study 1845132 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (10,000 U five times weekly or 150-450 U/kg)
Number of subjects: 65
Study 1845132 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (250 g/m2/day x 14, s.c.) combined with Ara-C (20 mg/m2/day x 14, s.c.)
Number of subjects: 65
Study 6365209 — intervention group
Group type: EXPERIMENTAL
Intervention: T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen)
Number of subjects: 232
Study 6365209 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, and 5-fluorouracil)
Number of subjects: 232
Study 6365209 — intervention group
Group type: EXPERIMENTAL
Intervention: T-CAF
Number of subjects: 232
Study 6365209 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 232
Study 30081019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg body weight, administered intravenously at weeks 0, 4, 8, and 12)
Number of subjects: 32
Study 30081019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 32
Study 27282848 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 585
Study 27282848 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 585